Semaglutide in Pediatric Craniopharyngioma

A multicentre retrospective case series reports outcomes after off-label semaglutide in 20 adolescents with craniopharyngioma-related obesity. After one year, mean BMI had fallen by 2.5 kg/m² and mean BMI Z-score by 0.5; 40% of participants had a BMI decrease of at least 10%^[1]. These are encouraging observations in a difficult clinical setting, but they are not the same as randomized evidence of efficacy or a general treatment recommendation.

Who was studied

The report included patients younger than 18 years with craniopharyngioma and obesity treated between 2019 and 2024 at multiple centres. The source population contained 139 children with craniopharyngioma, including 36 with obesity; 20 received semaglutide. At treatment initiation, the group's mean age was 14.0 years, mean BMI was 33.4 kg/m², and mean BMI Z-score was 3.2^[1].

Craniopharyngioma is a tumour near structures that regulate endocrine function and appetite. Its treatment and the disease itself can create complex long-term challenges. In this series, all participants had growth-hormone and TSH deficiency, while 19 of 20 had ACTH and AVP deficiency. That clinical context makes this population very different from a typical adolescent obesity trial^[1].

What changed during the year

The paper compared each patient's BMI trajectory before treatment with the trajectory after initiation. In the preceding year, the group gained a mean 3.5 kg/m² in BMI and 0.6 in BMI Z-score. In the year after semaglutide was started, mean BMI decreased by 2.5 kg/m² and BMI Z-score by 0.5. The paired comparisons reported p values below 0.001 and 0.004, respectively^[1].

A within-patient before-and-after comparison can be informative when a condition is rare, but it has an important limitation: there was no concurrent untreated or differently treated control group. Changes in clinical follow-up, diet, activity, other care, maturation, regression toward the mean, or selection of patients able to receive therapy could contribute to the observed pattern. The study reports an association, not a causal estimate.

Safety observations

Gastrointestinal side effects were reported in 30% of participants and described as mild. The authors reported no treatment discontinuations, no pituitary-insufficiency decompensation and no tumour recurrence during the reported treatment period^[1]. A case series of 20 people cannot reliably rule out uncommon harms, long-term effects, or events that would appear in a larger and more diverse population.

The study describes dose titration from 0.25 to 2 mg weekly, tailored to tolerance and clinical response. This is a description of the authors' retrospective practice, not dosing guidance. The paper specifically concerns specialist-managed adolescents with a rare endocrine history and does not establish an appropriate regimen for readers^[1].

Why off-label context matters

Off-label use means a clinician uses a licensed medicine outside the terms of a particular authorization. It does not mean a treatment has failed or is unsafe; it means evidence, monitoring, consent and local rules deserve particular attention. The authors identify semaglutide as off-label in this cohort. That should not be converted into an implication that it is a standard treatment for craniopharyngioma-related obesity.

A medicine's product information can describe approved uses and warnings, but it cannot answer the narrower question raised by this rare population. Specialist teams must consider the tumour history, endocrine replacement, nutritional status and other treatments. Our semaglutide overview and semaglutide safety material explain the broader evidence context.

What this study can and cannot tell us

The study supports a clear, limited conclusion: in this selected 20-patient retrospective series, semaglutide treatment was associated with reversal of the group's prior BMI gain over one year. It also provides a short-term description of recorded adverse effects and endocrine outcomes. It cannot tell us how treatment compares with other approaches, which patients are most likely to benefit, what happens after a year, or whether a different dose or care pathway would produce the same result.

A controlled prospective study would better separate treatment effect from time and selection. It would also need outcomes that matter beyond BMI, including function, quality of life, endocrine stability and longer-term safety. Evidence is preliminary. More data are needed. Until then, a rare-disease case series is a useful signal for research and specialist discussion, not a self-management template.

The numerical results should be read as group averages, not predictions for an individual child. The 40% figure for a BMI decrease of at least 10% also has a wide 95% confidence interval, from 19% to 64%. The interval reflects the small number of participants. That uncertainty does not erase the finding; it explains why replication is needed before it can guide routine care.

For broader background, readers can consult our semaglutide profile, semaglutide evidence summary, semaglutide safety section, semaglutide regulation page and GLP-1 overview. Those resources cannot determine whether a particular adolescent is a candidate for off-label care.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Pediatric endocrine and obesity care requires individualized clinical oversight. Always consult a qualified healthcare professional before making any decision about prescription treatment. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.